← All organizations
Highest phase reached
Phase 4
First clinical trial
Oct 1, 2000First marketed drug
Dec 4, 2024First NDA
Dec 4, 2024Last known activity
Dec 4, 2024
Timeline
1900s
- Jan 1, 1906
Norgine— Founded
2020s
- Dec 4, 2024
zenocutuzumab— NDA Organization
Drugs by trial phase (28 distinct, 62 trials)
Phase 4 (9 own, 0 via acquisition)
Phase 3 (9 own, 0 via acquisition)
Phase 2 (3 own, 0 via acquisition)
Phase 1 (4 own, 0 via acquisition)
Other trials (3 own, 0 via acquisition)
Indications
Studied for
- Ascites
- Brain Diseases
- Breast Neoplasms
- Colonic Neoplasms
- Colorectal Neoplasms
- Constipation
- Digestive System Diseases
- Esophagitis, Peptic
- Fatty Liver
- Fecal Impaction
- Fecal Incontinence
- Fibrosis
- Gastroesophageal Reflux
- Gastrointestinal Diseases
- Heartburn
- Hepatic Encephalopathy
- Hepatitis
- Hepatitis A
- Hepatitis, Viral, Human
- Hypertension, Portal
- Irritable Bowel Syndrome
- Liver Cirrhosis
- Liver Diseases
- Non-alcoholic Fatty Liver Disease
- Pathologic Processes
Marketed drugs (1)
Recent trials (50)
- NCT05697211CollaboratorPhase 4Feb 21, 2023
- NCT05436054CollaboratorPhase 4Oct 1, 2022
- NCT05177484CollaboratorPhase 3May 30, 2022
- NCT04487912CollaboratorPhase 4Nov 24, 2020
- NCT04073290CollaboratorPhase 4Oct 1, 2019
- NCT04070677CollaboratorN/AJun 15, 2019
- NCT03437265Lead sponsorPhase 1Apr 4, 2018
- NCT02273141Lead sponsorPhase 3Nov 1, 2014
- NCT02273167Lead sponsorPhase 3Oct 1, 2014
- NCT02254486Lead sponsorPhase 3Aug 1, 2014
- NCT02065726CollaboratorN/AFeb 25, 2014
- NCT01769040CollaboratorPhase 4Nov 1, 2012
- NCT01732692CollaboratorPhase 3Nov 1, 2012
- NCT01715272Lead sponsorPhase 1Oct 1, 2012
- NCT01714466Lead sponsorPhase 2Oct 1, 2012
Details
- Founded
- Amsterdam, NL Jan 1, 1906
- First NDA
- Dec 4, 2024
- Last known activity
- Dec 4, 2024
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy
- Accelerated approval